All In Biotech

Drug Trial Radar · NCT01583426

Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)

A Randomized Phase III Trial Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto)

Last checked: Nov 20, 2026Latest source record: Aug 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,229 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,229

Actual

Start

Jul 2012

Primary completion

Dec 2018

Study completion Dec 2018

Sponsor

Lead sponsor
GBG Forschungs GmbHAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Celgene Corporation; Roche Pharma AG
First posted
Apr 24, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Current guidelines as those from the AGO-Breast commission recommend for neoadjuvant breast cancer patients either a sequence of 4 cycles EC followed by 4 cycles of a taxane or 6 cycles of TAC based on previous large scale studies. Treatment of patients with HER2-positive disease should include also simultaneous application of trastuzumab. Solvent-based taxanes (paclitaxel, docetaxel) cause severe toxicities not only by the active agents itself but also by the solvents like cremophor. Nab-paclitaxel (Abraxane®) is a solvent-free formulation of paclitaxel encapsulated in albumin. It does not require premedication with corticosteroids or antihistamines to prevent the risk of solvent-mediated hypersensitivity reactions. This new formulation improves safety profile, allows higher dosing with shorter infusion duration, and produces higher tumor drug concentration. As neoadjuvant treatment does not only allow to compare competing treatment approaches with a very high quality (homogenous treatment population, precise assessment of response by histological assessment), but also to identify predictive markers, this trial will compare weekly nab-paclitaxel with solvent-based paclitaxel at their currently optimal doses. In case of HER2-positive tumor status patients receive Pertuzumab and Trastuzumab additionally.

Conditions

  • Tubular Breast Cancer Stage II
  • Mucinous Breast Cancer Stage II
  • Breast Cancer Female NOS
  • Invasive Ductal Breast Cancer
  • Tubular Breast Cancer Stage III
  • HER-2 Positive Breast Cancer
  • Inflammatory Breast Cancer Stage IV
  • Inflammatory Breast Cancer

Interventions

  • nab-PaclitaxelDrug

    nab-Paclitaxel 125 mg/m² weekly for 12 weeks

  • PaclitaxelDrug

    Paclitaxel 80 mg/m² weekly for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathological complete response (pCR=ypT0 ypN0) rates of neoadjuvant treatment of nab-paclitaxel with solvent-based paclitaxel as part of neoadjuvant treatment of operable or locally advanced primary breast cancer.Time frame: 24 weeks (time window + 3 weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Helios-Klinikum Berlin-Buch

    Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.